Mark Eisner, M.D., M.P.H.

EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER

Mark Eisner, M.D., M.P.H., has served as Vir’s Executive Vice President and Chief Medical Officer (CMO) since June of 2024. Dr. Eisner is responsible for leading Translational and Clinical Development, including Clinical Research, Development Operations, Biometrics, Clinical Pharmacology, Pharmacovigilance, and Risk Management, as well as Medical Affairs and Regulatory Affairs. He has deep immunology and infectious disease expertise as well as clinical development experience. Dr. Eisner has an impressive track record of leading teams during times of strategically evolving portfolios.

Prior to Vir, Dr. Eisner served as CMO at Sonoma Biotherapeutics, Inc., In this role, he led all development functions which included Biometrics, Regulatory, Clinical Science, Clinical Operations, Drug Safety, and Pharmacology. Prior to this, Dr. Eisner served as CMO at FibroGen where he led all Development functions, which included being the Head of China Clinical Development and Clinical Operations. Prior to FibroGen, Dr. Eisner spent nearly 11 years at Genentech and served as their Senior Vice President of Global Head of Product Development Immunology, Infectious Disease and Ophthalmology and was accountable for late-stage clinical development of many products.

Dr. Eisner completed his A.B. degree in human biology at Stanford University and his M.D. degree at the University of Pennsylvania School of Medicine. He also has an M.P.H. focusing on epidemiology from the University of California Berkeley, School of Public Health. He has an impressive list of publications and patents, honors and awards, and services for professional organizations.